Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer
根据可见的临床反应调整新辅助化疗方案是否重要？一项开放标签的随机II期研究比较了HER2阴性可手术乳腺癌患者的反应指导治疗和标准治疗方案。
期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2014-0400
Wang-Lopez, Qian; Mouret-Reynier, Marie-Ange; Savoye, Aude-Marie; Abrial, Catherine; Kwiatkowski, Fabrice; Garbar, Christian; DuBray-Longeras, Pascale; Eymard, Jean-Christophe; Lebouedec, Guillaume; Vanpraagh, Isabelle; Penault-Llorca, Frederique; Chollet, Philippe; Cure, Hervé
